🇺🇸 FDA

Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10688102

Combination treatment for migraine and other pain

AXSOME THERAPEUTICS, INC. · Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10688181

Cancer treatment combinations

The Regents of the University of California · Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10675302

Methods and compositions for targeted cleavage and recombination

Sangamo Therapeutics, Inc. · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10675304

Combination immunotherapies for treatment of cancer

PrimeVax Immuno-Oncology · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10675288

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10668129

Synergistic combination of neuronal viability factors and uses thereof

The Regents of the University of California · Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10668055

Cancer treatment using combinations of ERK and RAF inhibitors

Biomed Valley Discoveries, Inc. · Granted Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10653789

Polymer-drug conjugates for combination anticancer therapy

The Regents of the University of California · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10653689

Combination-based treatment method

Nektar Therapeutics · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10653710

Combination therapy for treating malignancies

Agios Pharmaceuticals, Inc. · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10646523

Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceuticall

AGAIN LIFE ITALIA SRL · Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10618967

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10610534

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10583134

Methods and therapeutic combinations for treating tumors

The Board of Regents of the University of Texas · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10583202

Homologous recombination in multipotent adult progenitor cells

Regents of the University of Minnesota · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10576096

Tumor-selective combination therapy

The Board of Regents of the University of Texas System · Granted Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10568873

Safranal-sorafenib combination therapy for liver cancer

UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10544223

Combination therapy with an anti-axl antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10532096

Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10532056

Therapeutic compositions, combinations, and methods of use

VERASTEM, INC. · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10526414

Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to i

VACCINEX, INC. · Granted Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10517860

Combination of pimavanserin and cytochrome P450 modulators

ACADIA Pharmaceuticals Inc. · Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10500277

Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and int

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10493030

Combination HIV therapeutic

Aphios Corporation · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted